HPK1 inhibitor NDI-101150 shows safety and antitumour activity in ccRCC

Tumour microenvironment and circulating biomarkers predict response to immunotherapy in advanced RCC

QoL maintained with sasanlimab plus BCG in high-risk, BCG-naive NMIBC

New MOAs in prostate cancer treatment - what’s next?

QoL improvements ID'd in phase 3 ARANOTE trial for mHSPC

BCG combined with mitomycin offers improved adjuvant treatment regimen for high-risk NMIBC

CtDNA useful biomarker for muscle-invasive bladder cancer patients who received perioperative durvalumab

Sasanlimab BCG combo improves outcomes in high-risk NMIBC

Managing gastrotoxicities for RCC treatment – Gastroenterologist's perspective

Metastasis-directed radiotherapy shows good prognosis for oligometastatic kidney cancer

Addition of radical prostatectomy to systemic treatment improves survival in oligometastatic prostate cancer

NeuroSAFE-guided RARP improves surgical precision for patients with localised prostate cancer